In October, when GSK agreed to a $2.2 billion settlement to resolve approximately 80,000 lawsuits | With a $2.2 billion ...

Tens of thousands of cancer-stricken patients filed personal injury and product liability lawsuits ... s liability to Zantac users. The truth began to emerge on August 10, 2022, when a Deutsche ...

announces the filing of a class action lawsuit on behalf of purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE: GSK) between February 5, 2020 and August 14, 2022, both dates ...

While the Company repeatedly claimed that scientific research did not support a correlation between Zantac ... August 15, 2022, thereby injuring investors further. What Is The Lawsuit About?

Today, prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP (“BLB&G”) filed a class action lawsuit ... to Zantac users. The truth began to emerge on August 10, 2022 ...

Shares in GSK fell around 9% this morning after a judge in a Delaware court gave the green light for tens of thousands of lawsuits claiming harm by gastrointestinal drug Zantac to proceed to trial.

which first hit the headlines in 2022. The common claim in the lawsuits is that a contaminant in Zantac (ranitidine) called N-nitrosodimethylamine (NDMA) – as well as other ranitidine products ...

In April 2020, the FDA requested that manufacturers cease selling Zantac ... lawsuits against GSK in the years that followed the recall. According to the complaint, on August 10, 2022, a Deutsche ...

announces the filing of a class action lawsuit on behalf of purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE: GSK) between February 5, 2020 and August 14, 2022, both dates ...